1:53 PM
 | 
Jun 01, 2018
 |  BC Extra  |  Company News

FDA rebuffs third biosimilar Herceptin

Amgen Inc. (NASDAQ:AMGN) said Friday it received a complete response letter from FDA for ABP 980. This marks the third CRL the agency has issued for a biosimilar of Herceptin trastuzumab. Amgen declined to disclose details of the letter. ABP 980 is partnered with Allergan plc (NYSE:AGN)....

Read the full 212 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >